Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Stratoimmune
Fukuoka, Fukuoka, Japan
- Ownership
- Private
- Development stage
- Other
01
Overview
Stratoimmune is a Japanese biotechnology startup focused on developing innovative immunotherapies for autoimmune diseases. The company's core technology is based on research into Ras guanyl-releasing proteins (RasGRPs) conducted by Chief Science Officer and Co-founder Shinsuke Yasuda, a professor at Tokyo Medical and Dental University. Stratoimmune is developing antisense oligonucleotide (ASO) therapies targeting RasGRP4 to treat inflammatory and autoimmune conditions, including dermatomyositis, polymyositis, and rheumatoid arthritis. The company is actively seeking clinical trial and manufacturing partnerships to advance its pipeline.
- Therapeutic areas
- ImmunologyRheumatology
- Modalities
- Antisense oligonucleotideBiologic
- Industry
- Biotech
02
Partnerships
Nissan Chemical CorporationTokyo Medical and Dental UniversityCellTech Innovation
Beyond the preview
Go deeper on Stratoimmune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stratoimmune.